Evaluating programmed death‐ligand 1 (PD‐L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study - Concepedia

Concepedia

Publication | Open Access

Evaluating programmed death‐ligand 1 (PD‐L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study

DOI Full Paper Access

42

Citations

21

References

2021

Year

Bruna Cerbelli, Ilaria Girolami, Albino Eccher, Leopoldo Costarelli, Silvia Taccogna, Renzo Scialpi, Maria Benevolo, Teresa Lucante, Piero Luigi Alò, Francesca Stella,

Abstract

Two different assays (the 22C3 PharmDx assay and SP263 assay) for PD-L1 in HNSCC showed high agreement. These data suggest that these two assays are interchangeable in the selection of patients with HNSCC for immunotherapy.

References

	Year	Citations

Page 1